DailyIQ
Last updatedUpdating…

HUM·Humana Inc.

$424.83
+4.45 (+1.06%)
High
$432.15
Open
$421.61
Market Cap
50.20B
52W High
$456.50
Low
$413.45
P. Close
$424.83
P/E
39.25
52W Low
$163.11
Fwd P/E
25.34
DailyIQ Est.
$474.83
Inst. Ownership
42.0%
Short Interest
2.34%
Days to Cover
2.2
Div. Yield
0.84%
Next Ex-Div
~Dec 25
Technical Score (1D)
84
BULLISH
News Sentiment
63
BULLISH
On Oct 13, Humana announced that 95 % of its Medicare members would now be enrolled in plans rated four stars or higher, up from 20 % a year earlier, citing a new scorecard released that month covering 2027 that shows the insurer has moved from failing to meeting the benchmark. The upgrade was said to improve Washington’s bonus payments and strengthen Humana’s competitive positioning in the Medicare market. On the same day, the company disclosed a joint venture with BlackRock’s HPS Investment Partners to manage nearly 150 CenterWell Senior Primary Care clinics, replacing its previous partnership with Welsh, Carson, Anderson & Stowe. The deal, valued at approximately $2.8 billion, was expected to close in Q4 and was described as a means to enhance Humana’s financial flexibility and support future growth. Truist confirmed that the new joint venture would improve financial flexibility and support growth, noting that it replaces the existing joint ventures with Welsh, Carson, Anderson & Stowe and that the agreement is projected to close in Q4. Truist maintained a hold rating and a $475 price target for Humana following the announcement.
LOW TARGET
$280 -34.1%
2 analysts
MEAN TARGET
$462 +8.6%
21 analysts
HIGH TARGET
$596 +40.3%
11 analysts
PRICE RANGE
$280.00 - $596.00
SB / B / H / S / SS
8/8/16/1/1
DAILYIQ EST.
$474.83 (+11.8%)
Sector
Healthcare
Industry
Healthcare Plans
Exchange
NYQ
Country
United States
Website
Symbol
HUM
Description
Humana Inc. is a U.S.-based healthcare company primarily focused on providing medical and specialty insurance products. Its core business revolves around two key segments: Insurance and CenterWell. Humana offers a range of health plans, including medical care, supplemental benefits, and prescription drug coverage, catering to individuals, employer groups, and government programs like Medicare and Medicaid. The company's value proposition extends to administrative services and specialized offerings such as dental, vision, and military healthcare through the TRICARE program. Humana differentiates itself through integrated services, including pharmacy benefit management, primary care centers, and home health solutions, providing a comprehensive approach to healthcare delivery for its members.
Bought (1Y)
0 shares
$0
Sold (1Y)
0 shares
$0
HILZINGER KURT J-
Award/Grant238 shares2026-09-30
Nundy ShantanuChief Medical Officer
Award/Grant2,549 shares2026-09-01
Crawford Frederick John-
Award/Grant544 shares2026-08-01
Smith Paul John-
Award/Grant544 shares2026-08-01
HILZINGER KURT J-
Award/Grant233 shares2026-06-30
83/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
20.4%
Revenue CAGR
-7.8%
Current Ratio
2.00x
Debt / Equity
0.70x
Return on Equity
6.7%
Earnings Summary
Humana Inc. is a U.S.-based healthcare company that delivers medical and specialty insurance products through its Insurance and CenterWell segments, offering a broad array of plans including Medicare Advantage, supplemental benefits, and prescription drug coverage, while also providing administrative services and specialized offerings such as dental, vision, and military healthcare. Operating within the competitive healthcare plans sector, Humana differentiates itself through integrated services, pharmacy benefit management, and home health solutions. In the most recent quarters, Humana’s revenue has shown a steady upward trajectory, rising from $29.2 billion in Q4 2024 to $32.7 billion in Q3 2025, a 12.5% year‑over‑year increase, while EPS swung from a loss of $2.16 in Q4 2024 to a modest $3.24 in Q3 2025, reflecting a gradual recovery in profitability; the company beat estimates in Q1 2025 and Q2 2025 but missed in Q4 2025 where EPS fell to a loss of $3.96 despite revenue growth. Historically, Humana has maintained a positive revenue growth trend over the past four quarters, with EPS improving from a loss in Q4 2024 to a profit in Q1 2025, yet the company has experienced volatility in earnings, alternating between losses and modest gains, indicating a pattern of earnings instability despite consistent revenue expansion. Recent news highlights a significant upgrade in Medicare Star Ratings, with 95% of members now enrolled in four‑star plans, which is expected to enhance bonus payments and competitive positioning; additionally, a $2.8 billion joint venture with BlackRock’s HPS Investment Partners to manage CenterWell clinics is slated to close in Q4, potentially improving financial flexibility.

EPS

EstBeatMiss
$-6.14$-1.42$3.30$8.03$12.75Q2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$-1.01 - -
Q2'26$7.29$7.61+4.3%
Q1'26$10.16$10.31+1.5%
Q4'25$10.57$-3.96-137.5%
Q3'25$2.83$3.24+14.6%
Q2'25$5.87$6.27+6.9%

Revenue

EstBeatMiss
$31.1B$33.9B$36.8B$39.7B$42.6BQ2'25Q3'25Q4'25Q1'26Q2'26Q3'26
QtrEstActual+/−
Q3'26$41.3B - -
Q2'26$41.0B$40.9B-0.3%
Q1'26$39.4B$39.6B+0.7%
Q4'25$35.5B$32.6B-8.1%
Q3'25 - $32.6B -
Q2'25 - $32.4B -

Market Data

HUM Stock Snapshot

BULLISH84/100
$424.83+$4.45 (1.1%)
Market cap
50.20B
P/E ratio
39.3
Day range
$413.45 – $432.15
News sentiment
63/100 · Bullish
Analyst target
$461.50 (+8.6%)
Consensus
Hold · 34 analysts
52-week range+160.5% off low · -6.9% from high
$163.11$456.50
Price $424.83 DailyIQ Est. $474.83

Humana Inc. screens well technically, with price sitting near its 52-week high. Institutional coverage is thorough here, so shifts in analyst expectations show up in price quickly.

Reverse DCF

What growth is priced into HUM?

RICH

At today's price, Humana Inc. needs to grow free cash flow about 57.7% a year for the next 10 years to justify its valuation at a 7.84% cost of capital. Over its actual history it has compounded free cash flow at 3.3% a year, so the market is asking for 54.4 percentage points above its own delivered rate. On that basis HUM looks priced above what its own growth record supports.

Implied FCF growth
57.7%
Historical FCF CAGR
3.3%
Growth gap
+54.4 pts
Verdict
RICH
Discount rate (WACC)
7.84%
Beta
0.69

Behaviour On Record

What HUM's own history says about today's numbers

Realized volatility (21d)
43.5% 85th pct
Below its peak
-25.5%
vs 200-day average
+40.9%
Up days (1y)
54%

Humana Inc. is currently running 43.5% annualised volatility over the last 21 sessions. Measured against HUM's own 13 years of daily returns rather than a market-wide average, that is the 85th percentile — elevated for this stock, against a typical reading of 25.3%. The distinction matters because a number that looks calm for one stock is turbulent for another, and the absolute figure on its own tells you neither.

HUM is trading -25.5% below its running peak. Across 12 full years on file, its median worst-drawdown-in-a-year was -22.5%, and the deepest was -49.9% in 2024. The current drawdown is already deeper than this stock's typical annual low point, which puts it in the part of its range where past recoveries began — and where past declines also continued.

Price sits +40.9% from its 200-day moving average. Against every other day in its history, that gap ranks at the 98th percentile — a wider gap than this stock usually carries. Over the past year HUM closed higher on 54% of sessions, and it is currently 1 session into a falling streak.

On October specifically: over 13 years of records, HUM finished the month higher 7 of 13 times, with a median return of +4.2% and an average of +4.3%. Its strongest month historically has been May at +6.5% on average, its weakest January at -3.8%. Seasonality is a weak signal on its own — a decade is a small sample and regimes change — but it is a real distribution rather than a rule of thumb.

Overnight risk is measurable too: HUM has opened more than 2% away from the prior close in 103 of 3,268 sessions (3.2% of the time), with the largest gaps running +8.9% and -11.8%. For anyone holding through an event, that rate is a better guide to overnight exposure than the intraday range.

Across the last 3 dated reports on file, HUM moved an average of 1.8% in the session after earnings, closing higher 2 of those 3 times, with a median move of +1.8% and a largest of -1.8%.

All figures computed from 3,269 daily closes between 2013-10-15 and 2026-10-13, split-adjusted, recomputed daily. Percentiles are against HUM's own 13-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of HUM's sector?

Humana Inc. sits in the Health Care sector, currently ranked 3rd of 12 GICS sectors by relative-strength rotation score (leading).

Sector rank
#3 of 12
Sector state
Leading
Sector rotation score
91

Options Market

What is the options market pricing for HUM?

CallsPuts

For Humana Inc.'s nearest expiry (2026-10-16, 2 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.65), with at-the-money implied volatility around 60.8%. The options market is pricing roughly a ±4.0% move by that expiry — a range of about $407.56–$441.18.

Put/call ratio (2026-10-16)
0.65
ATM implied volatility
60.8%
Total open interest
59,434
Expected move by 2026-10-16
±4.0% ($407.56–$441.18)

Analyst Rating Changes

Are analysts turning bullish or bearish on HUM?

Mizuho most recently reiterated its rating on Humana Inc. to Outperform on Oct 13, 2026 with a price target of $495 (from $468). Over the last 90 days, coverage has run 6 upgrades against 1 downgrade, a net bullish lean.

Latest action
Mizuho — Outperform
90-day upgrades
6
90-day downgrades
1
Net rating momentum
+5
DateFirmActionRatingPrice target
Oct 13, 2026MizuhoMaintainedOutperform$468 → $495
Oct 12, 2026UBSMaintainedNeutral$405 → $495
Oct 12, 2026Truist SecuritiesMaintainedHold$415 → $475
Oct 12, 2026OppenheimerMaintainedOutperform$475 → $525
Oct 12, 2026Raymond JamesUpgradeMarket Perform → Outperform$520
Oct 9, 2026BarclaysMaintainedOverweight$515 → $582
Oct 9, 2026OppenheimerMaintainedOutperform$405 → $475
Oct 9, 2026BairdUpgradeNeutral → Outperform$390 → $596
Oct 7, 2026Cantor FitzgeraldUpgradeNeutral → Overweight$300 → $460
Sep 25, 2026BarclaysUpgradeEqual-Weight → Overweight$407 → $515
Aug 10, 2026JP MorganMaintainedNeutral$316 → $393
Aug 5, 2026Morgan StanleyUpgradeUnderweight → Equal-Weight$249 → $370

Peers & ETF holders

HUM peers & ETF holders

News Sentiment Analysis

Sentiment gathered from recent headlines

63/100
Strong NegativeNeutralStrong Positive
MODERATELY BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

10+ articles
What did this article say?
Humana announced that 95% of its Medicare members will now be enrolled in plans rated four stars or higher, up from 20% a year earlier. The company cited a new scorecard released this month covering 2027, which shows the insurer has moved from failing to meeting the benchmark. This shift is expected to improve Washington’s bonus payments and enhance Humana’s competitive positioning in the Medicare market. The upgrade reflects stronger plan performance and could support future revenue growth.
What did this article say?
Humana announced a joint venture with BlackRock’s HPS Investment Partners to manage nearly 150 CenterWell Senior Primary Care clinics, replacing its previous partnership with Welsh, Carson, Anderson & Stowe. The deal, valued at approximately $2.8 billion, will see BlackRock acquire the equity stake in the clinics while CenterWell continues operations. The transaction is expected to close in Q4 and is intended to enhance Humana’s financial flexibility and support future growth. The announcement followed a strong year‑to‑date share price performance, suggesting market confidence in the partnership’s potential value creation.
What did this article say?
Truist confirmed that Humana’s new joint venture with BlackRock, involving the acquisition of a $2.8 billion stake in CenterWell Senior Primary Care clinics, will improve the company’s financial flexibility and support growth. The agreement replaces Humana’s existing joint ventures with Welsh, Carson, Anderson & Stowe and is projected to close in Q4. Truist maintained a hold rating and a $475 price target for Humana following the announcement.
What did this article say?
Humana’s shares climbed 11% on Friday after the company announced a recovery in its Medicare Advantage ratings and highlighted its involvement in a planned NIH-backed cancer vaccine initiative. The rally was part of a broader biotech sector surge that also lifted Moderna and Lumentum. Investors viewed the Medicare rating improvement and potential vaccine partnership as evidence of renewed growth prospects for Humana’s health‑insurance business.
What did this article say?
Humana reported operating efficiency improvements and better Star Ratings, yet underwriting margins remain pressured and cash flow recovery is uncertain. The company trades at a forward non‑GAAP earnings multiple of 42.28x, well above the sector median, reflecting high expectations for margin recovery and regulatory clarity. Membership and CenterWell segment growth are positive, but high benefit ratios and reliance on regulated subsidiary cash limit parent‑level financial flexibility. The analyst maintains a Hold rating, noting that only sustained profitability and cash flow improvements would justify the premium valuation.
What did this article say?
In early October 2026, Humana announced Medicare Advantage coverage for BlueWind Medical’s Revi tibial neuromodulation system, targeting urgency urinary incontinence among its 11 million enrollees. The decision follows multi‑year OASIS clinical data and a new AMA CPT code, signaling a push toward home‑managed, advanced therapies. Humana’s improved 2027 star ratings—95 % of members in 4‑star or higher plans—support a narrative of margin recovery through enhanced benefits. The coverage expansion is expected to strengthen Humana’s quality bonus mix and attract higher‑valued contracts. Overall, the move is viewed as a strategic step toward restoring profitability while expanding service offerings.
What did this article say?
Humana shares rose 16.8 % in pre‑market trading after Robert W. Baird upgraded the stock to Outperform and lifted its price target to $596 from $390. The upgrade followed Humana’s announcement that 95 % of its Medicare Advantage members are enrolled in plans rated 4.0 stars or higher for 2027, up from 25 % in the 2025 cycle. Baird cited improved federal quality ratings, conservative benefit design, and easing medical cost growth as catalysts for higher earnings potential. The analyst’s confidence that Humana can generate over $35 in adjusted EPS in 2028 underpins the optimistic outlook. The move reflects a broader belief in Humana’s ability to drive profitability through quality‑focused strategy.
What did this article say?
Humana’s stock climbed 12% after the company reaffirmed its full‑year 2026 guidance of at least $9 in adjusted earnings per common share. The announcement also reiterated that 95% of its Medicare Advantage members are enrolled in plans with at least four stars for 2027, a significant improvement over prior years. The rally was driven by the market’s confidence in Humana’s ability to maintain high quality ratings and meet earnings expectations. The positive reaction underscored the importance of star ratings in securing federal quality bonuses and competitive member benefits.
What did this article say?
Humana announced that 95% of its Medicare Advantage members are enrolled in plans with at least four stars for 2027, a record high. The company’s member‑weighted star rating rose to 4.17, the highest ever achieved. The improvement is expected to increase bonus payments tied to high‑star plans and lift monthly revenue per member. The announcement drove the stock up more than 15% on Friday, marking the strongest performance in the S&P 500 that day.

Technical Analysis

Real-time indicators across multiple timeframes

84
BULLISH
Momentum rank against about 1,000 stocks and ETFs for this timeframe.
Unlock full technicals
Create a free account to access more indicators and deeper timeframe data.
Institutional & Hedge Fund Ownership
25 tracked managers · $17.41B combined position · 18 adding, 7 trimming, 0 unchanged (latest 13F filings)
ManagerTrendShares Held% of Co.Position ValueFiled
BlackRock, Inc.▲ Buy10,417,8038.74%$4.14B2026-08-07
Vanguard Group Inc▲ Buy14,261,86011.97%$3.65B2026-01-29
Geode Capital Management, LLC▲ Buy3,369,7572.83%$1.34B2026-08-12
JPMorgan Chase & Co▲ Buy3,234,6372.71%$1.26B2026-08-12
FMR LLC (Fidelity)▲ Buy2,913,7632.45%$1.16B2026-08-13
Goldman Sachs Group Inc▲ Buy2,299,8891.93%$913.56M2026-08-14
Norges Bank▼ Sell1,748,4141.47%$694.51M2026-08-12
Invesco Ltd.▼ Sell1,478,7881.24%$587.40M2026-08-14
Morgan Stanley▼ Sell1,349,0661.13%$535.88M2026-08-13
Capital Research Global Investors▲ Buy1,116,9900.94%$443.46M2026-08-12
Northern Trust Corp▼ Sell1,115,1980.94%$442.98M2026-08-13
Capital World Investors▲ Buy1,022,4250.86%$406.12M2026-08-12
Wellington Management Group LLP▲ Buy765,3550.64%$304.01M2026-08-14
Bank of America Corp▼ Sell703,6150.59%$279.49M2026-08-14
Marshall Wace, LLP▲ Buy545,9780.46%$216.87M2026-08-13
Citadel Advisors LLC▲ Buy449,0220.38%$178.36M2026-09-02
Millennium Management LLC▲ Buy352,6980.30%$140.10M2026-08-14
Neuberger Berman Group LLC▲ Buy267,3690.22%$106.20M2026-08-13
Glenview Capital Management, LLC▼ Sell254,2160.21%$100.98M2026-08-14
Gotham Asset Management, LLC▲ Buy224,8600.19%$89.32M2026-08-14
Balyasny Asset Management L.P.▲ Buy221,4540.19%$87.97M2026-08-14
AQR Capital Management LLC▲ Buy222,4080.19%$86.81M2026-08-14
Adage Capital Partners GP, L.L.C.▲ Buy210,1200.18%$83.46M2026-08-14
Citigroup Inc▲ Buy209,7870.18%$83.33M2026-08-03
D. E. Shaw & Co., Inc.▼ Sell204,5430.17%$81.25M2026-08-14
Q2 2026 flow:3.13M sh bought ($1.24B)1.60M sh sold ($635.38M)net +1.53M sh (+$605.29M)
Congressional Trading Activity
15 disclosed trades · ~$120.0K est. traded value · 8 buys, 7 sells
MemberChamberStateTypeAmountTradedFiled
Alan ArmstrongSenateOK▲ Buy$1K - $15K2026-03-272026-07-21
Julia LetlowHouseLA05▼ Sell$1K - $15K2026-02-102026-03-12
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-11-122025-12-15
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-312025-11-21
Lisa McClainHouseMI09▼ Sell$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-10-302025-11-21
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-09-252025-10-22
Julia LetlowHouseLA05▲ Buy$1K - $15K2025-08-082026-01-13
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-08-052025-09-12
Lisa McClainHouseMI09▲ Buy$1K - $15K2025-06-242025-08-13
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-05-302025-06-06
Rob BresnahanHousePA08▼ Sell$1K - $15K2025-05-152025-06-09
Gilbert CisnerosHouseCA31▼ Sell$1K - $15K2025-04-292025-05-06
Gilbert CisnerosHouseCA31▲ Buy$1K - $15K2025-02-262025-03-06
Rob BresnahanHousePA08▲ Buy$1K - $15K2025-02-252025-03-27